# Martina Brueckmann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/martina-brueckmann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,836 |
| Field | Diabetes Treatment and Management |
| h-index | 58 |
| i10-index | 145 |
| Last Known Institution | Boehringer Ingelheim (Germany) |
| OpenAlex ID | https://openalex.org/A5016763799 |
| ORCID iD | https://orcid.org/0000-0003-1215-0746 |
| Works | 225 |

## Researcher papers

Showing 12 of 13.

- [Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure](https://scholariq.org/papers/cardiovascular-and-renal-outcomes-with-empagliflozin-in-heart-failure/)
- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials](https://scholariq.org/papers/sglt2-inhibitors-in-patients-with-heart-failure-with-reduced-ejection-fraction-a/)
- [Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials](https://scholariq.org/papers/impact-of-diabetes-on-the-effects-of-sodium-glucose-co-transporter-2-inhibitors/)
- [The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial](https://scholariq.org/papers/the-sglt2-inhibitor-empagliflozin-in-patients-hospitalized-for-acute-heart/)
- [Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction](https://scholariq.org/papers/effect-of-empagliflozin-on-the-clinical-stability-of-patients-with-heart-failure/)
- [Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status](https://scholariq.org/papers/effect-of-empagliflozin-on-cardiovascular-and-renal-outcomes-in-patients-with/)
- [Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function](https://scholariq.org/papers/cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across-the/)
- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)
- [Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction](https://scholariq.org/papers/effect-of-empagliflozin-in-patients-with-heart-failure-across-the-spectrum-of/)
- [Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial](https://scholariq.org/papers/evaluation-of-the-effects-of-sodium-glucose-co-transporter-2-inhibition-with/)
- [Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis](https://scholariq.org/papers/prognostic-value-of-plasma-n-terminal-pro-brain-natriuretic-peptide-in-patients/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)

## Researcher university

- [Boehringer Ingelheim (Germany)](https://scholariq.org/institutions/boehringer-ingelheim-germany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.